ESG 2009 (Rome)

ESG 2009 (Rome)
October 22, 2009 amarone


Satellite Symposium at the 8th Congress of the European Society of Gynecology

Selective progesterone receptor modulators (SPRM) are a new class of compounds with great potential in the treatment of uterine fibroids. The presentations in this symposium discussed the pharmacology of SPRM and their effect on the endometrium, before moving on to review recent clinical outcomes with SPRM and identifying how they might be used in the management of uterine fibroids.


Hall Pio X, MONUMENTAL COMPLEX OF SANTO SPIRITO IN SAXIA, Borgo Santo Spirito 1, 00193 Rome, Italy
Friday, 11th September 2009 | 09:10 – 10:40

Bart Fauser, The Netherlands
Andrea Genazzani, Italy

  • 09:10 – 09:15 | Introduction: Why clinicians must re-evaluate what they can offer symptomatic patients | Bart Fauser, The Netherlands
  • 09:15 – 09:35 | SPRM class: Mode of action, and do SPRMs differ from each other? | Philippe Bouchard, France
  • 09:35 – 09:55 | Features of selective progesterone receptor modulator (SPRM) associated endometrial changes | George Mutter, USA
  • 09:55 – 10:15 | The proof of evidence: PGL4001 (ulipristal acetate) Phase II clinical data| Lynnette Nieman, USA
  • 10:15 – 10:35 | SPRMs in clinical practice: Are there any implications for surgery? | Jacques Donnez, Belgium
  • 10:35 – 10:40 | Question and answer session | Andrea Genazzani, Italy

Send this to friend